Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Luye Pharma Group Ltd. (HK:2186)
HKEX:2186
Luye Pharma Group (2186) Stock Price & Analysis
0 Followers
2186 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$2.34 - HK$4.00
Previous CloseHK$2.69
Volume5.57M
Average Volume (3M)11.76M
Market Cap
HK$9.94B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)17.3
Beta0.94
Next Earnings
Aug 28, 2024EPS EstimateN/A
Last Dividend Ex-Date
Jun 29, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding3,761,670,643
10 Day Avg. Volume9,180,000
30 Day Avg. Volume11,758,688
Standard Deviation0.10
R-Squared0.20
Alpha-0.00545
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Luye Pharma Group News
PremiumCompany Announcements
Luye Pharma’s LY03010 Clears FDA Inspection
PremiumCompany Announcements
Luye Pharma’s New Parkinson’s Drug Approved in China
PremiumCompany Announcements
Luye Pharma’s New Schizophrenia Treatment Approved
PremiumCompany Announcements
Luye Pharma Expands Alzheimer’s Treatment into Japan
PremiumCompany Announcements
Luye Pharma Group’s AGM Concludes with Positive Outcomes
Options Prices
Currently, No data available
---
Ownership Overview
33.43%
Insiders
1.99% Mutual Funds
2.17% Other Institutional Investors
62.42% Public Companies and
Individual Investors
2186 FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was HK$2.34 and its highest was HK$4.00 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Currently, no data Available
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 28, 2024 which is in 55 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 27, 2024. The company reported HK$0.11 earnings per share for the quarter, beating the consensus estimate of HK$0.107 by HK$0.003.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Overvalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of HK$0.06 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,761,670,700 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of HK$0.11 in its last earnings report, beating expectations of HK$0.107. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in HK:2186
---
Luye Pharma Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.05%
12-Months-Change
Fundamentals
Return on Equity
4.61%
Trailing 12-Months
Asset Growth
3.04%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd is a major drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company's operations are primarily centered in China with treatments focused on oncology, cardiovascular diseases, and metabolism. The vast majority of the company's revenue is generated from oncology drugs, followed by cardiovascular drugs. Luye's growth strategies include continued innovation and globalization while improving its market share in China in the three key therapeutic areas, namely oncology, cardiovascular system and alimentary tract, and metabolism. In addition, Luye intends to strengthen international cooperation while accelerating the launch of product candidates internationally.
---
2186 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering 2186
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+40.33%
reiterated a sell rating 3 months ago
Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.33% per trade.
---